Revolution Medicines Doses First Patient in RMC-5127 Clinical Trial for RAS G12V-Selective Inhibitor

Revolution Medicines has dosed the first patient in a clinical trial evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor. The trial aims to assess safety, tolerability, pharmacokinetics, and antitumor activity in patients with RAS G12V-mutated solid tumors, including pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. RMC-5127 is designed to inhibit the oncogenic RAS(ON) form of the RAS G12V variant, a common driver of RAS-addicted human cancers. The trial will also evaluate the candidate in combination settings.